Skip to main content

Table 1 Main characteristics of the four COVID-19 vaccines approved in Europe as of July 28, 2021

From: Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI)

Developer Commercial name Type Number of doses Dosage interval
Pfizer–BioNTech Comirnaty mRNA-based 2 3–12 weeks
Moderna COVID-19 Vaccine Moderna mRNA-based 2 4 weeks
AstraZeneca Vaxzevria Adenovirus vector-based 2 4–12 weeks
Johnson and Johnson - Janssen Pharmaceuticals COVID-19 Vaccine Janssen Adenovirus vector-based 1